2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: MPH.

Poster-Neuroimmunology and disease models

October 25, 2021

Clinical and Diagnostic Spectrum of Optic Neuritis: A Single-Center Retrospective Study of Disorders Associated with Multiple Sclerosis, Aquaporin-4 Antibody, and Myelin Oligodendrocyte Glycoprotein Antibody

Background: Optic neuritis (ON) is an immune-mediated optic neuropathy associated with multiple immune-mediated neurological conditions....

Read More →

Poster-Multidisciplinary Care

October 25, 2021

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Background: Historically, multiple sclerosis (MS) has been underdiagnosed among African Americans with MS (AAwMS). Recent evidence suggests...

Read More →

Poster-Internet and Information Services

October 25, 2021

Using a University Canvas Learning Management System to Increase Knowledge about MS: The Multiple Sclerosis Student Advocates Program As an Educational Intervention

Background: About 1 million adults live with MS in the US (National Multiple Sclerosis Society NMSS, 2019), an autoimmune disease with no...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data

Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC